Celgene's Revlimid Effective, Safe in Early Myeloma

Bloomberg.com: U.S.: "Celgene Corp.'s Revlimid, a treatment for a deadly cancer of the bone marrow, was safer and helped patients live longer when used in combination with a lower-than- usual dose of an immune-suppressing drug. Revlimid helped 91 percent of patients newly diagnosed with multiple myeloma live at least 18 months when used with a lower dose of dexamethasone, an immune suppressor, according to a study presented at the American Society of Hematology in Atlanta today. Eighty percent of patients lived that long when a higher dose of dexamethasone was given with Revlimid, researchers said. "